Sepracor ends Xopenex copromotion with Abbott
Executive Summary
Sepracor's copromotion deal with Abbott's Ross division for Xopenex (levalbuterol) will end on Dec. 31. Sepracor is moving its sales force in-house as it ramps up for the launch of its insomnia agent Estorra (eszopiclone). Sepracor will expand sales force to approximately 1,250 reps. Estorra has been "approvable" at the agency since Feb. 27 (1"The Pink Sheet" March 8, 2004, p. 34)...